Refine
Has Fulltext
- yes (73)
Is part of the Bibliography
- yes (73)
Year of publication
Document Type
- Journal article (73)
Language
- English (73) (remove)
Keywords
- Biochemie (60)
- Neurospora crassa (4)
- Physiologische Chemie (2)
- bone morphogenetic proteins (2)
- receptor signalling (2)
- ATP carrier (1)
- ATP synthase (1)
- ATPase mutants (1)
- Aminosäuren (1)
- Apoptosis (1)
- B cell receptors (1)
- B cells (1)
- BMP (1)
- BMP antagonist (1)
- Biologie (1)
- Bone morphogenetic protein-2 (1)
- Bone regeneration (1)
- BrdU-Hoechst (1)
- CYR61 (1)
- Cancer (1)
- DNA mediated gene transfer (1)
- Dicyclohexylcarbodiimid (1)
- E. coli atp operon (1)
- Ectopic bone formation (1)
- Escherichia coli (1)
- Escherichia coli-derived recombinant human bone morphogenetic protein-2 (1)
- IL-2 (1)
- IL-4 (1)
- IL-7 (1)
- Interleukin 2 (1)
- Interleukin 4 (1)
- Interleukin 4 (human) (1)
- Interleukin 7 (1)
- Interleukin-4 (1)
- Mechanisms (1)
- Mund-Kiefer-Gesichts-Chirurgie (1)
- Myofibroblast differentiation (1)
- NMR (1)
- NMR spectroscopy (1)
- Oncogene (1)
- Oralchirurgie (1)
- Platelet-derived growthfactor (1)
- Polylactide-co-glycolide (1)
- Proliferation (1)
- R. sphaeroidesl (1)
- Receptor (1)
- Recombinant (1)
- Recombinant DNA (1)
- Smooth-muscle-cells (1)
- Structure-function (1)
- T-Lymphozyt (1)
- T-cells (1)
- TGF-beta (1)
- TGF-β superfamily (1)
- Tumor cell (1)
- amino acid sequence (1)
- antagonist (1)
- antigen binding antibody fragment (Fab) (1)
- automated solid-phase Edman degradation (1)
- b/c1 complex (1)
- bacteriophage lambda (1)
- cDNA (1)
- carbenes (1)
- cartilage induction (1)
- cell binding (1)
- cell cycle (1)
- cell proliferation (1)
- cloning (1)
- conduction de protons (1)
- crystal structure (1)
- cytokines (1)
- drug design (1)
- drug design/partial agonists (1)
- electrostatic potential (1)
- expression plasmid (1)
- flow cytometry (1)
- gene (1)
- gene expression (1)
- growth and differentiation factor 5 (1)
- hematopoietic receptors (1)
- human growth factor (1)
- hybrid-selected translation (1)
- in vitro and in vivo expression (1)
- in vitro expression (1)
- inhibition of H+ translocation (1)
- interleukin 2 (1)
- interleukin 4 (1)
- interleukins (1)
- ligand-receptor complex (1)
- ln vitro mutagenesis (1)
- mRNA and gene (1)
- membrane proteins (1)
- membrane receptor signaling (1)
- mitochondrial ADP (1)
- mitochondrially translated (1)
- molecular recognition (1)
- multiple myeloma (1)
- neutralizing antibodies (1)
- nucleotide sequence (1)
- packaging (1)
- partial agonists (1)
- polycistronic mRNA (1)
- proliferation assays (1)
- protein pathway (1)
- protein structure (1)
- protein-protein recognition (1)
- proteines membranaires (1)
- proteolipid (1)
- proton conduction (1)
- screening (1)
- sequence subunit (1)
- signal transduction (1)
- signaling (1)
- subunit stoichiometry (1)
- translational initiation (1)
- von Willebrand type C domain (1)
Institute
- Theodor-Boveri-Institut für Biowissenschaften (72)
- Julius-von-Sachs-Institut für Biowissenschaften (4)
- Lehrstuhl für Tissue Engineering und Regenerative Medizin (3)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (2)
- Klinik und Poliklinik für Mund-, Kiefer- und Plastische Gesichtschirurgie (2)
- Augenklinik und Poliklinik (1)
Sonstige beteiligte Institutionen
Multiple myeloma (MM) represents a haematological cancer characterized by the pathological hyper proliferation of antibody-producing B-lymphocytes. Patients typically suffer from kidney malfunction and skeletal disorders. In the context of MM, the transforming growth factor β (TGFβ) member Activin A was recently identified as a promoter of both accompanying symptoms. Because studies have shown that bone morphogenetic protein (BMP)-2-mediated activities are counteracted by Activin A, we analysed whether BMP2, which also binds to the Activin A receptors ActRII and ActRIIB but activates the alternative SMAD-1/5/8 pathway, can be used to antagonize Activin A activities, such as in the context of MM. Therefore three BMP2 derivatives were generated with modified binding activities for the type II (ActRIIB) and/or type I receptor (BMPRIA) showing either increased or decreased BMP2 activity. In the context of MM these BMP2 muteins show two functionalities since they act as a) an anti-proliferative/apoptotic agent against neoplastic B-cells, b) as a bone-formation promoting growth factor. The molecular basis of both activities was shown in two different cellular models to clearly rely on the properties of the investigated BMP2 muteins to compete for the binding of Activin A to the Activin type II receptors. The experimental outcome suggests new therapeutic strategies using BMP2 variants in the treatment of MM-related pathologies.